TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00614744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normothermic Control
Description: Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
Study: NCT03424239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: 5mg zoledronic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium citrate + vitamin D
Description: Chewable 500mg calcium citrate with 500 International Units (IU) Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 1000IU Vitamin D3 gummy
Study: NCT05871242

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus crispatus M247
Description: Patient who have received probiotic Lactobacillus crispatus M247
Study: NCT00770211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin) (20 Units)
Description: The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
Study: NCT03031704

Intervention type: PROCEDURE
Intervention: Endoscopic mucosectomy
Description: Performing adenoma resection through standardized endoscopic mucosectomy of duodenal adenoma.
Study: NCT02509403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils infused Perineal Hygiene wipe
Description: Each participant will be asked to complete a treatment period of one month's duration. At the start of the study, the participants will be asked to fill-out a baseline questionnaire and will be given a month's supply of the perineal hygiene towel with instructions about its use. At day 15, 30 and 45 follow-ups will be conducted.
Study: NCT03109106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCT Arm
Description: PCT-guided antibiotic therapy per study protocol
Study: NCT02957565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Questionnaires
Description: Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos
Description: Participant watches 2 short videos that show actors playing doctor and patient roles, discussing different cancer-related symptom treatment options. Each video is about 4 minutes long and discusses the same content, but setting of each video is different.
Study: NCT01248221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C]-Spirulina platensis and 99mTc sulfur colloid
Description: The subject will consume the test meal containing 13C-Spirulina and 99mTc sulfur colloid in no more than 10 minutes. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C]-Spirulina platensis and 99mTc sulfur colloid
Description: The subject will consume the test meal containing 13C-Spirulina and 99mTc sulfur colloid in no more than 10 minutes. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
Study: NCT01822821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
Study: NCT01610271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Barrier System
Description: ABS is a device that emits a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
Study: NCT06025851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-human CCL24 monoclonal antibody (CM-101)
Description: Intravenous Infusion of Anti-human CCL24 monoclonal antibody (CM-101)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT03625206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training
Description: These training sessions aim to modify a selective attention bias towards threat and a tendency to interpret ambiguous situations in threatening ways

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control training
Description: These exercises are matched to the task demands of the modules of cognitive bias modification training
Study: NCT03359239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg administered by IV infusion every 3 weeks (21 \[+/-2\] days) for up to 12 months in the adjuvant setting and up to 24 months in the metastatic setting.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGV001
Description: PGV001: up to ten total doses of PGV001with helper peptides. The product is prepared within the ISMMS . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.~A dose of PGV001 consists of the following:~Up to ten synthetic peptides - 100μg (0.01 mL, 10 mg/mL) per peptide. One tetanus helper peptide - 100μg (0.01 mL, 10 mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: 1.4 mg (0.7 mL, 2 mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 0.19 mL
Study: NCT02376855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eConsult
Description: An electronic consultation or eConsult is a secure message consult that allows specialists to provide advice on cases without seeing a patient face to face. They contain a reason for consult, any relevant tests, procedures or reports. The responsibility lies with the primary care provider to act, or not act on the advice as they deem fit.
Study: NCT04491708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: The participants attended two half-hour Pilates exercise classes twice a week, for one month, to familiarize themselves with the exercises and to learn the 5 Pilates' principles. After the learning period, two experimental sessions were performed: a Mat Pilates session and a Reformer apparatus Pilates session. The order of each session was randomized and drawn beforehand. Each experimental session lasted about one and a half hours and the interval between the sessions was 48 hours. Participants were asked to not perform any exercise and to refrain from food or fluids except water eight hours prior to each experimental session. Prior to the start of the experimental sessions, participants received a standard breakfast of 321 kcal that was 76% (61 g) carbohydrate, 8% (6,7 g) protein, 16% (5,9) fat, provided by the study researchers. All sessions were conducted at the same time in the morning, and the room temperature (22°C) and humidity (40-50%) were controlled during the whole session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: The participants attended two half-hour Pilates exercise classes twice a week, for one month, to familiarize themselves with the exercises and to learn the 5 Pilates' principles. After the learning period, two experimental sessions were performed: a Mat Pilates session and a Reformer apparatus Pilates session. The order of each session was randomized and drawn beforehand. Each experimental session lasted about one and a half hours and the interval between the sessions was 48 hours. Participants were asked to not perform any exercise and to refrain from food or fluids except water eight hours prior to each experimental session. Prior to the start of the experimental sessions, participants received a standard breakfast of 321 kcal that was 76% (61 g) carbohydrate, 8% (6,7 g) protein, 16% (5,9) fat, provided by the study researchers. All sessions were conducted at the same time in the morning, and the room temperature (22°C) and humidity (40-50%) were controlled during the whole session.
Study: NCT01919476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bagel
Study: NCT03219879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-administered continuation therapy
Description: The intervention includes eight therapy sessions of approx. 50 minutes duration delivered over the telephone by trained psychotherapists over a time period of six months. The intervention is grounded in the principles of psychological continuation therapy and relapse prevention, and includes strategies such as transferring helpful elements of acute-phase cognitive-behavioral therapy (CBT) for depression to daily life. T-CT is offered in addition to usual care.
Study: NCT01919476

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bagel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cream Cheese
Study: NCT03219879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care without any study-related intervention
Study: NCT01721070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab (SUF NT) 15 mcg
Description: Period 1: One dose of SUF NT 15 mcg administered sublingually
Study: NCT01919476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond Butter
Study: NCT02973152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroplasty
Description: This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reinnervation
Description: For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
Study: NCT00100893

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IH636 grape seed proanthocyanidin extract
Description: Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage
Study: NCT01721070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg
Description: Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
Study: NCT04878640

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
Description: patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
Study: NCT03533855

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CS plus FRFSE
Description: we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence
Study: NCT02679651

Intervention type: OTHER
Intervention: Ultrasound of the foot
Description: An ultrasound will be used to determine the thickness of the fat pad
Study: NCT04878640

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
Description: patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
Study: NCT02678988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-1000 G2
Description: The device will contain TCZ (180 milligrams per milliliter \[mg/mL\]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).
Study: NCT03657862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: application of 38% silver diamine fluoride solution
Description: SDF solution was painted onto the surface of the carious lesion of the tooth

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: application of a placebo (tonic water)
Description: tonic water was painted onto the surface of the carious lesion of the tooth
Study: NCT02207673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery
Study: NCT03866187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd155-hIi-HBV low dose formulation
Description: Subjects in group A1 receive one dose of ChAd155-hIi-HBV low dose formulation at Day 1, by intramuscular injection in the deltoid of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd155-hIi-HBV high dose formulation
Description: Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm.
Study: NCT02678988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-1000 G2
Description: The device will contain TCZ (180 milligrams per milliliter \[mg/mL\]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-1000 G2
Description: The device will contain TCZ (180 milligrams per milliliter \[mg/mL\]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).
Study: NCT03866187

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd155-hIi-HBV high dose formulation
Description: Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd155-hIi-HBV high dose formulation
Description: Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm.
Study: NCT01978015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: travoprost and timolol maleate fixed combination
Description: travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost and maleate timolol fixed combination
Description: Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
Study: NCT02679651

Intervention type: OTHER
Intervention: Pedobarograph Measurements
Description: This non-invasive device measures the force and pressure of the foot while standing and walking.

Intervention type: OTHER
Intervention: Pedobarograph Measurements
Description: This non-invasive device measures the force and pressure of the foot while standing and walking.
Study: NCT03866187

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-HBV high dose formulation
Description: Subjects in groups B1 and B3 receive one dose of MVA-HBV high dose formulation at Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in group C1 receive three co-administered doses of the vaccine at Days 57, 113 and 169 and subjects in group C2 receive one co-administered dose of the vaccine at Day 169, by intramuscular injection in the deltoid of the dominant arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
Study: NCT02679651

Intervention type: OTHER
Intervention: Manchester Foot Pain and Disability Index
Description: This is a patient completed questionnaire that assesses level of function from the past month specific to foot pain.

Intervention type: OTHER
Intervention: Manchester Foot Pain and Disability Index
Description: This is a patient completed questionnaire that assesses level of function from the past month specific to foot pain.
Study: NCT02806895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110
Study: NCT03866187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
Study: NCT02806895

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02730338

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity aerobic and resistance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial support

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychosocial support
Study: NCT02678988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-1000 G2
Description: The device will contain TCZ (180 milligrams per milliliter \[mg/mL\]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-1000 G2
Description: The device will contain TCZ (180 milligrams per milliliter \[mg/mL\]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-1000 G2
Description: The device will contain TCZ (180 milligrams per milliliter \[mg/mL\]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFS-NSD
Description: The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFS-NSD
Description: The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFS-NSD
Description: The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFS-NSD
Description: The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFS-NSD
Description: The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFS-NSD
Description: The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
Study: NCT02204007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D imaging & surrogate bone model
Description: 3D imaging \& surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging